Can lurbinectedin target all cancer cells?

Can lurbinectedin kill every cancer cell type?

Lurbinectedin mainly targets transcription in cancer cells. It binds DNA minor grooves and disrupts RNA polymerase II, stopping gene expression needed for tumor growth. This works against cells that rely heavily on transcription, but it does not kill every cancer cell type. Some tumors resist because they repair DNA damage better or use alternative transcription pathways.

Does lurbinectedin work uniformly across all tumors?

Lurbinectedin gained approval for relapsed small cell lung cancer based on data showing response rates around 35%. It is also studied in soft tissue sarcoma and ovarian cancer. Different cancers show varying sensitivity. Solid tumors with defective DNA repair systems respond better. Tumors that can bypass transcription inhibition show little effect.

Why do some cancers resist lurbinectedin?

Resistance often comes from enhanced nucleotide excision repair or increased drug efflux pumps. These mechanisms remove or repair the damage lurbinectedin causes. Clinical reports document cases where tumors progressed despite treatment, which shows that the drug cannot reach or affect every cell in a tumor.

When does the lurbinectedin patent expire?

The composition of matter patent covering lurbinectedin expires in 2034. [1]